- Title
- The clinical relevance of MOG antibody testing in cerebrospinal fluid
- Creator
- Reynolds, Molly; Tan, Irene; Lechner-Scott, Jeannette; Fabis-Pedrini, Marzena; Fok, Anthony; John, Nevin; Kneebone, Chris; Yiannikas, Con; Brown, David A.; Kermode, Allan G.; Reddel, Stephen; Dale, Russell C.; Nguyen, Kristy; Brilot, Fabienne; Ramanathan, Sudarshini; Australasian MOGAD Study Group,; Merheb, Vera; Lee, Fiona X. Z.; Trewin, Benjamin P; Lerch, Magdalena; Shah, Snehal; Wolfe, Nigel; Buzzard, Katherine
- Relation
- Annals of Clinical and Translational Neurology Vol. 11, Issue 9, p. 2514-2519
- Publisher Link
- http://dx.doi.org/10.1002/acn3.52163
- Publisher
- John Wiley & Sons
- Resource Type
- journal article
- Date
- 2024
- Description
- Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is diagnosed by serum MOG-immunoglobulin G (MOG-IgG) in association with typical demyelination. 111/1127 patients with paired CSF/serum samples were seropositive for MOG-IgG. Only 7/1016 (0.7%) seronegative patients had CSF-restricted MOG-IgG. While 3/7 patients had longitudinally extensive transverse myelitis, four had a confirmed alternate diagnosis (three multiple sclerosis, one CNS vasculitis). In a national referral setting, CSF-restricted MOG-IgG had a low sensitivity (2.63%, 95%CI 0.55–7.50%) and low positive predictive value (1.97%, 95%CI 0.45–8.13%). We strongly recommend serum as the preferred diagnostic biospecimen, and urge caution in the interpretation of CSF-restricted MOG-IgG in patients without clinico-radiological features consistent with MOGAD.
- Subject
- MOGAD; diagnosis; controlled study; immunology; demyelination; clinical significance
- Identifier
- http://hdl.handle.net/1959.13/1518015
- Identifier
- uon:57214
- Identifier
- ISSN:2328-9503
- Rights
- x
- Language
- eng
- Reviewed
- Hits: 212
- Visitors: 211
- Downloads: 0